middle.news
Cynata Therapeutics Narrows Loss as Key Trials Near Data Readouts
4:02pm on Thursday 26th of February, 2026 AEDT
•
Healthcare
Read Story
Cynata Therapeutics Narrows Loss as Key Trials Near Data Readouts
4:02pm on Thursday 26th of February, 2026 AEDT
Key Points
Half-year loss narrowed to $2.66 million from $3.65 million
Revenue declined 10% to $1.77 million, including a $1.71 million R&D tax rebate
Phase 3 osteoarthritis and Phase 2 aGvHD trials nearing completion with results due Q2 2026
Cash balance of $2.6 million plus $1.2 million raised via ATM facility extends runway to mid-2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cynata Therapeutics (ASX:CYP)
OPEN ARTICLE